# Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

> **NCT02471404** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 939 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Inadequate Glycaemic Control

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Saxagliptin
- **DRUG:** Glimepiride
- **DRUG:** Placebo for dapagliflozin
- **DRUG:** Placebo for saxagliptin
- **DRUG:** Placebo for glimepiride

## Key facts

- **NCT ID:** NCT02471404
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-21
- **Primary completion:** 2017-03-13
- **Final completion:** 2017-03-13
- **Target enrollment:** 939 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471404, "Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02471404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*